COVID-19 Funding Opportunities

The MSI STEM Research & Development Consortium (MSRDC) - Additional funding for COVID-19-related research

The MSI STEM Research & Development Consortium (MSRDC)

The Icahn School of Medicine at Mount Sinai has become a partner institution of the MSI STEM Research & Development Consortium (MSRDC). This partnership offers significant advantages to Mount Sinai researchers and the consortium members through collaborative work. It also offers funding opportunities that would otherwise be unavailable to Mount Sinai researchers.  MSRDC awards are “other transactions” rather than traditional grants or contracts. These non-competed awards bypass solicitation, allowing for a direct connection between collaborative partners and government program managers. This unusual funding mechanism connect collaborative partners with Minority-Serving Institutions (MSI), such as Historically Black Colleges and Universities (HBCUs), to work on government projects.

Some Advantages – Skip The Line:

  • Access a community of researchers and partners
  • Leverage unique funding vehicles to secure direct, non-competed awards
  • Work together to produce a Scope of Work (SOW) and a Request for Proposal (RFP)
  • Move your idea from concept to award in as few as 90 days, (or fewer)

Some of the federal agencies involved include:

  • Centers for Disease Control and Prevention (CDC)
  • National Institutes of Health (NIH)
  • Food and Drug Administration (FDA)
  • Department of State (DOS)
  • Department of Defense (DoD)
  • Department of Education (DoE)
  • Homeland Security
  • Communications-Electronics Research Development Center (CERDEC)
  • Biomedical Advanced Research and Development Authority (BARDA)
  • Army Material Systems Analysts Activity (AMSAA)
  • Department of Transportation

MSRDC Innovation Prospectus
MSRDC  Presentation

Submit your capabilities to get started.  For additional information or assistance, email Anthony Smalls.

Anthony Smalls, MBA
Program Manager
Research Operations & Infrastructure
Icahn School of Medicine at Mount Sinai
New York, NY 10029
Phone:  (212) 241- 0640

If you have any questions for MSRDC, please contact them below:
info@msrdconsortium.org (All other inquiries)
busdev@msrdconsortium.org (For questions about working with our partners and member institutions)
awards@msrdconsortium.org (For those who already have an active research award)

Hours:   Monday to Friday, 9:00 am to 5:00 pm EST
Phone: (202) 684-7953

 

MSHS Guideline for Deans Funding for COVID-19 Research

Send one page proposals, biosketch, and budget—as one PDF—to covidpilotgrants@mssm.edu.

General Notices

07/12/2021 to 02/16/2022 - Special Empahsis Notice (SEN): Health Services Research to Advance Health Equity

The purpose of this Special Emphasis Notice (SEN) is to inform the research community of the Agency for Healthcare Research and Quality’s (AHRQ) interest in receiving health services research grant applications that propose innovative and evidence-based interventions that advance the nation’s goal of achieving equity in the delivery of healthcare services including reducing disparities in quality of care, patient safety, healthcare utilization and access, and ultimately, health outcomes.

Deadline: 12-Jun-2021 , 16-Jun-2021 , 01-Aug-2021 , 07-Sep-2021 , 25-Sep-2021 , 05-Oct-2021 , 12-Oct-2021 , 16-Oct-2021 , 01-Nov-2021 , 07-Jan-2022 , 25-Jan-2022 , 01-Feb-2022 , 05-Feb-2022 , 12-Feb-2022 , 16-Feb-2022 , 01-May-2022 , 07-May-2022 , 25-May-2022 , 05-Jun-2022 , 12-Jun-2022 , 16-Jun-2022 , 01-Aug-2022 , 07-Sep-2022 , 25-Sep-2022 , 05-Oct-2022 , 12-Oct-2022 , 16-Oct-2022 , 01-Nov-2022 , 07-Jan-2023 , 25-Jan-2023 , 01-Feb-2023 , 05-Feb-2023 , 12-Feb-2023 , 16-Feb-2023

More Information

NOT-AI-20-066 - Notice of Early Expiration of NOT-AI-20-051 Notice of Special Interest (NOSI): Select Research Areas for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

NOT-HD-20-017 - Notice of NICHD Participation in NOT-EB-20-012 "Notice of Change in Application Due Date for PAR-19-215 Due to Public Health Emergency for United States Coronavirus Disease 2019 (COVID-19)"

Notice Number: NOT-HD-20-017

The purpose of this Notice is to inform potential applicants that the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is participating in NOT-EB-20-012 “Notice of Change in Application Due Date for PAR-19-215 Due to Public Health Emergency for United States Coronavirus Disease 2019 (COVID-19)”.

More Information

NOT-MH-20-061 - Notice Announcing the Availability of Common Data Elements for Research Related to the Public Health Emergency caused by Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-MH-20-061

The purpose of this Notice is to extend the data-harmonization effort at the National Institute of Mental Health (NIMH) announced in NOT-MH-15-009 to research protocols pertaining to the public health emergency caused by Coronavirus Disease 2019 (COVID-19), the disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

NIMH has already made a significant investment in a data repository to hold human subjects data related to mental illness and related fields. This repository allows data from multiple sources to be aggregated and easily accessed by the research community. However, the data repository is most useful when research laboratories collect data using the same set of data elements. With this Notice, NIMH offers guidance on the use of consensus-derived common data elements (CDEs) pertaining to mental health outcomes that were previously discussed in NOT-MH-15-009and a set of newly available measures regarding experiences during the COVID-19 public health emergency and exposures to the SARS-CoV-2 virus (the virus that causes COVID-19). The goal of this Notice is to reduce proliferation of one-off survey items and to facilitate data integration, collaboration, and comparisons across data sets.

More Information

Notice of Information: Contributing to the Global COVID-19 Crisis Response by Allowing Some NCI-supported Projects to be Redirected to COVID-19-related Research During the Crisis

Notice Number: NOT-CA-20-054

The COVID-19 pandemic is a global health crisis that has engaged the attention of researchers who want to be able to contribute their expertise and resources toward a better understanding of the impacts of SARS-CoV-2 infection and COVID-19 disease on cancer patients’ disease progression, response to therapy, care delivery, or survivorship.

More Information

Notice of Participation of National Institute of Nursing Research (NINR) in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional")

Notice Number: NOT-NR-20-005

The purpose of this Notice is to inform applicants that the National Institute of Nursing Research (NINR) will participate, effective immediately, in PA-20-135 “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)”.

More Information

NSF Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19)

  • NSF is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.
  • NSF encourages the research community to respond to this challenge through existing funding opportunities.
  • In addition, NSF invites researchers to use the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency with regard to availability of or access to data, facilities or specialized equipment as well as quick-response research on natural or anthropogenic disasters and similar unanticipated events. Requests for RAPID proposals may be for up to $200K and up to one year in duration. Well-justified proposals that exceed these limits may be entertained. All questions should be directed either to a program officer managing an NSF program with which the research would be aligned or to rapid-covid19@nsf.gov.
  • Complete guidance on submitting a RAPID proposal may be found in Chapter II.E.1 of the NSF Proposal and Award Policies and Procedures Guide.

More Information

Notice of Intent

Notice of Intent to Publish Research Opportunity Announcements (OTA-21-015) for the Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Initiative

Notice of Intent to Publish Research Opportunity Announcements (OTA-21-015) for the Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Initiative

Purpose: This Notice is to alert the community that NIH plans to publish Research Opportunity Announcements (ROAs) as part of the Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) initiative. The solicited research will improve understanding of and develop strategies to prevent and treat post-acute manifestations of SARS-CoV-2 infection across the lifespan. The initial ROAs are expected to be published by mid-February 2021.

Projects will be funded utilizing NIH’s Other Transaction Authority (OTA), which offers flexibility and the ability to engage partners in collaborative innovation and problem solving. Initial awards are anticipated to be made in early March 2021. This Notice is being provided for informational purposes to allow potential applicants additional time to develop responsive applications. NIH reserves the right to modify the scope and objectives as described in this Notice. Final scope, objectives, and requirements will be set forth in the published ROAs.

Background: Some COVID-19 survivors report experiencing symptoms beyond the usual recovery time from the infection. In some cases, new symptoms and findings are reported that appear linked to the timing of acute infection but emerge subsequently and evolve over time.

Reported symptoms range from mild to incapacitating and can persist for months following acute disease. These symptoms and findings (i.e., post-acute sequelae) are reported in different organs and systems and can adversely affect overall quality of life.

The magnitude of the public health impact of these sequelae is currently unknown but potentially profound, given the numbers of individuals across the age spectrum who have been and will be infected with SARS-CoV-2, the virus that causes COVID-19. It is a public health priority to understand and develop strategies to prevent and treat PASC.

Research Initiative Details.The goal of the PASC Initiative is to systematically advance our understanding of the recovery process after SARS-CoV-2 infection and to prevent and treat PASC. Toward these ends, the overall PASC Initiative is designed to address three fundamental scientific questions: – What is the biologic basis of the heterogeneity in recovery from SARS-CoV-2 infection? – For those patients who do not fully recover or develop new symptoms/sequelae, what is the incidence/prevalence, clinical spectrum, and underlying biology? – What interventions might improve recovery after SARS-CoV-2 infection and prevent long-term disability due to PASC?In implementing the PASC initiative, NIH will solicit research proposals to understand recovery after SARS-CoV-2 infection and PASC. The PASC initiative will leverage a variety of platforms, including large and long-standing longitudinal studies; large-scale EHR/health systems-based cohort studies; COVID-19 clinical trials/networks; and COVID-19 registries, observational and clinical studies. These will be augmented by utilization of mobile and digital health strategies for patient recruitment, data collection, and follow-up. Applicants will be encouraged to leverage multidisciplinary teams to generate the critical data necessary to rapidly enhance understanding of PASC, including its epidemiology, risk factors for illness severity and outcomes, natural history, and pathophysiology. Exploratory clinical trials testing strategies to treat symptoms and prevent progression of SARS-CoV-2 infection to PASC are also an important part of this initiative and will be the subject of subsequent solicitations. Together, these activities will constitute a rigorous and comprehensive research program on PASC across the spectrum of COVID-19 clinical presentation, across diverse populations, and throughout the lifespan, leading to findings and innovative treatment and preventive strategies that are applicable to all who are affected, including populations that bear a disproportionate burden of SARS-CoV-2 infection.NIH intends for projects funded under this program to be part of a coordinated Consortium that will collectively pursue the goal of understanding, treating, and preventing PASC by collaboratively developing common protocol elements; adopting common data elements; and sharing data, biospecimens, and knowledge within the Consortium and with the broader research community.

Toward these ends, NIH plans initially to publish three ROAs to solicit applications for:

ROA #1: Clinical Research Studies targeting three domains: (a) Clinical Case-Based Recovery Meta-Cohort, (b) Autopsy Studies, and (c) EHR-/Health Systems-Based Analyses. Applications for this ROA may encompass one or more of these three domains.

a. Clinical Case-Based Recovery Meta-Cohort At the heart of the PASC Initiative is the SARS-CoV-2 Recovery Cohort, a collaborative meta-cohort that will leverage ongoing fit-for-purpose cohorts as well as new cohorts to facilitate the rapid launch of multi-disciplinary observational and mechanistic research on the incidence, risk factors, and mechanisms involved in PASC morbidity. This meta-cohort will bring together clinical cohorts of research participants across the lifespan with a history of SARS-CoV-2 infection, COVID-19, and/or PASC across the lifespan, of two main types:

i. Acute: Cohort studies with well-characterized pre-infection and/or acute infection baseline data and established plans for continued follow-up from the acute infection to understand the natural history and underlying biology of the heterogeneous recovery after SARS-CoV-2 infection.

ii. Post-acute: Cohort studies of the post-acute phase enrolling participants with SARS-CoV-2 infection, COVID-19, or PASC with appropriate comparison participants and conducting intensive investigation of relevant organ injury and other system dysfunction and continued longitudinal follow-up of health outcomes. The studies funded will constitute a meta-cohort encompassing inclusive participation reflective of appropriate diversity and enrolling adults and children. For the purposes of studies of adults, NIH anticipates assembling from across all the contributing cohorts a total of at least 20,000 cases of SARS-CoV-2 infection/COVID-19 cases and at least 1,000 PASC cases. For the purposes of studies of children, we anticipate assembling from across the contributing cohorts a total of at least 10,000 cases of SARS-CoV-2 infection/COVID-19 cases and at least 500 PASC cases. Preference may be given to applicants capable of studying large numbers of cases and appropriate comparison participants; this will be further detailed in the ROA. Applicants proposing smaller samples will be expected to provide strong justification for their approach based on other considerations, e.g., special population characteristics or deep pre-infection phenotyping, special investigations of specific organ dysfunction, etc.

b. Autopsy Studies: The goal of this effort is to provide in-depth histopathologic analysis of a broad range of organs and tissues in order to identify injury due to SARS-CoV-2 infection and/or its sequelae that lead to or contribute to PASC. Investigators will be expected to submit tissues to a biobank for distribution across the Consortium and more broadly with the research community.

c. EHR-/Health Systems-Based Studies: The goal of this effort isto advance the understanding and management of the post-acute effects of COVID-19 across the lifespan by: making innovative use of real world data such as electronic health records, health systems data, and other large data sets; by further expanding capabilities of existing data resources; leveraging health-systems based protocols to inform PASC clinical characterization through patient survey-based symptom reporting; and by working in an integrated fashion with other components of the coordinated NIH response to address PASC.

ROA #2: Clinical Science Core, for which applicants will be expected to:

•Foster collaboration across the Consortium; coordinate and provide logistical support(scheduling, meetings, communication platforms) for the PASC investigator consortium and all relevant working groups/committees, including platforms to solicit and incorporate patient viewpoints; facilitate use of toolkits of common data elements, surveys/questionnaires, and mobile health tools; incorporate use of various consent processes (e.g., e-consent) as applicable; interface with IRBs; and support the literature review in PASC.

•Provide expertise and statistical input on clinical study design, implementation, execution, and monitoring, including advising and coordinating the development and implementation of protocols/sub-study protocols; develop manual of procedures, case report forms, identification and selection of surveys and questionnaires, and recruitment strategies to promote inclusive participation; assure delivery of high-quality data, including mobile data, to the Data Resource Core; and develop monitoring procedures for study performance and safety.

Support and provide expertise in clinical research study data management, data quality control, study monitoring, statistical analyses, sample size calculations, data reports for oversight and monitoring boards and regulatory entities, analysis expertise and support for phenotyping in adults and children, including the acute and post-acute manifestations, at a clinical and biological level.

•Provide framework/infrastructure and statistical expertise for results analysis, interpretation and dissemination, and development of final phenotype characterization and diagnostic algorithms. •Coordinate receipt of the collection, analysis, deposition, and central management of patient biospecimens, transfer to the PASC biorepository (to be identified by NIH at a later date), and linkage of these biospecimens to clinical data in order to provide critical tools and resources for future PASC research.

ROA #3: Data Resource Core, for which applicants will be expected to:

•Facilitate the standardized collection of clinical data (i.e., usage of common data elements) and data harmonization, assist research projects with linking these data with other data, including but not limited to: publicly available sources (e.g., Census data, Area Deprivation Index, etc.), electronic health records (EHR) and others as needed, as well as perform quality control, data curation, and analyses, and provide data informatics tools.

•Maximize the value of the collective data sets and enable interoperability with other NIH COVID-19 research resources by supporting studies with a cloud-based data “workbench;” promoting adoption of common data elements and harmonized definitions of key variables; and facilitating seamless integration into existing large-scale well-curated genotypic and phenotypic data sets.

•Create a data coordination and analytics framework to compile and link data from extant clinical studies/networks, biosamples, imaging, EHR and related records data, mobile health data and other non-traditional data sources; and provide access to datasets for analysis by the research community.Additional ROAs may be issued in the future as needed.

Researchers planning to apply are strongly encouraged to read all three of these interrelated research opportunities when they are published.

Inquiries: Please direct all inquiries to: NHLBI_OTA@mail.nih.gov

NIH Administrative Supplements

Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for administrative supplements are considered prior approval requests (as described in Section 8.1.2.11 of the NIH Grants Policy Statement) and will be routed directly to the Grants Management Officer of the parent award. Although requests for administrative supplements may be submitted through this FOA, there is no guarantee that funds are available from the awarding IC or for any specific grant. All applicants are encouraged to discuss potential requests with the awarding IC. Additionally, prior to submission, applicants must review the awarding IC’s web site to ensure they meet the IC’s requirements.

When applying please follow the additional instructions in the corresponding NOSI and include the NOSI # as indicated.

More Information

Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)

The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for Urgent Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent award. Only applications submitted in response to an Urgent Guide Notice published by an IC will be allowed to apply to this FOA.

When applying please follow the additional instructions in the corresponding NOSI and include the NOSI # as indicated.

More Information

Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)

The National Institutes of Health (NIH) hereby notify the applicant community that funds may be available for applications based on a presidentially declared disaster under the Stafford Act, a public health emergency declared by the Secretary, HHS, or other local, regional or national disaster. Applications in response to Emergency Notices of Special Interest (NOSIs) will be routed directly to the NIH awarding component signed on to the Emergency NOSI.

Only applications submitted in response to an Emergency NOSI published by an IC will be allowed to apply to this FOA.

More Information

Notice of Changes to Funding Opportunities

Notice of NIDA's Participation in NOT- MD-21-008 "Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities"

The purpose of this Notice is to inform potential applicants that the National Institute on Drug Abuse (NIDA) will participate, effective immediately in NOT-MD-21-008, Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities”.

More Information

NOT-HL-20-806 - NHLBI confirms participation in NOT-OD-20-119, NOT-OD-20-120, and NOT-OD-20-121 (Research on COVID-19 Testing among Underserved and/or Vulnerable Populations)

Notice Number: NOT-HL-20-806

More Information

NOT-OD-20-157 - Notice to Clarify and Correct Eligibility in Notices of Special Interest under the Rapid Acceleration of Diagnostics Underserved Populations (RADx-UP) Program

Notice Number: NOT-OD-20-157

This notice makes corrections to clarify eligibility information in NOT-OD-20-119 “Notice of Special Interest (NOSI): Emergency Competitive Revisions for Social, Ethical, and Behavioral Implications (SEBI) Research on COVID-19 Testing among Underserved and/or Vulnerable Populations” and NOT-OD-20-120 “Notice of Special Interest (NOSI): Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations” and a deletion to correct responsiveness information for NOT-OD-20-119.

In both NOT-OD-20-119 and NOT-OD-20-120 where it

Currently states:

Eligibility

Eligible existing grants that can be revised in response to this NOSI are limited to eligible non-fellowship active research and resource grants and cooperative agreements. Currently funded grantees may apply for work that is related to their funded project, whether within the scope or outside of the scope of the current project, regardless of the time remaining on the current project. Grants currently in a no-cost extension are eligible to apply

is Updated to read:

Eligibility

Active research and resource grants, cooperative agreements, and small business grants (SBIR and STTRs) are eligible to apply. NRSA training and fellowship grants, and career development awards are not eligible to apply for funding. Currently funded recipients may apply regardless of the time remaining on the current project.Grants currently in a no-cost extension are eligible to apply.

For NOT-OD-20-119, an error is corrected by removal of a bulleted item, related to “Applications nonresponsive to this NOSI…”.

Where it is indicated:

Applications nonresponsive to terms of this NOSI will not be considered.The following types of projects would generally not be appropriate and may be deemed non-responsive:

Remove the bulleted line:

  • Projects that have limited testing capacity, that do not include FDA-authorized testing strategies or present a plan to incorporate approved testing strategies

More Information

NOT-OD-20-156 - Notice of Change to Funding Announcement (NOT-OD-20-048) by the Office of Research on Women's Health (ORWH), " Research on the Health of Women of Understudied, Underrepresented and Underreported (U3) Populations (Admin Supp Clinical Trial Optional)"

Notice Number: NOT-OD-20-156

The purpose of this notice is to inform potential applicants that the Office of Research on Women’s Health (ORWH) has made some changes, effective immediately, in NOT-OD-20-048, “Notice of Special Interest: Research on the Health of Women of Understudied, Underrepresented and Underreported (U3) Populations (Admin Supp Clinical Trial Optional)”.

The following text has been added to reflect changes in the NOSI (NOT-OD-20-048).

The Office of Research on Women’s Health (ORWH) announces the availability of administrative supplements to support research highlighting health disparities among women in the US who are underrepresented, understudied, and underreported (U3) in biomedical research. The proposed research must address at least one objective from the strategic goals 1, 2, or 3 of the 2019-2023 Trans-NIH Strategic Plan for Women’s Health Research “Advancing Science for the Health of Women.”

ORWH is encouraging application submissions and is seeking to support studies on the SARS-CoV-2 virus or COVID-19 disease in alignment with efforts across NIH to develop and implement effective therapeutics and vaccines and to accelerate research on technologies to validate and improve programs that will overcome barriers and increase uptake of effective therapeutics and vaccines at the point of care. Within the focus of this funding opportunity announcement, research topics of interest could include investigating the risk factors associated with COVID-19 disease prevalence among NIH-designated health disparity populations, women living in underserved rural or urban settings, pregnant and lactating women, women frontline healthcare workers, women with low socioeconomic status, and women experiencing homelessness or having justice system involvement.

Topics addressing intersectional and community-based research for older underserved women, residents of skilled nursing or long-term care facilities, and women providing care in the home to aging, disabled populations, or children (i.e., maternal caregiving) are areas of interest.

Research involving qualitative and quantitative techniques to assess social and behavioral processes that affect SARS-CoV-2 infection vulnerability and disease severity in underrepresented, understudied, and underreported (U3) populations are also areas of interest.

Proposals are encouraged to incorporate a variety of media, such as graphic medicine or other arts-based approaches to engage with underrepresented, understudied, and underreported (U3) populations to achieve the goals of the applications.

More Information

NOT-OD-20-149 - Notice of Correction to RFA-OD-20-013 "Emergency Awards: RADx-UP Coordination and Data Collection Center (CDCC) (U24 Clinical Trial Optional)" for Award Information about Clinical Trials

Notice Number: NOT-OD-20-149

This notice corrects RFA-OD-20-013 “Emergency Awards: RADx-UP Coordination and Data Collection Center (CDCC) (U24 Clinical Trial Optional)” in Section II. to indicate that this funding opportunity accepts applications that either propose or do not propose clinical trial(s).

This funding opportunity announcement is corrected for Section II. Award Information – Clinical Trial?, as follows:

Currently reads:

Not Allowed: Only accepting applications that do not propose clinical trial

Is modified to read:

Optional: Accepting applications that either propose or do not propose clinical trial(s)

More Information

NOT-HL-20-801- National Heart, Lung, and Blood Institute -Notice of NHLBI Participation in NOT-OD-20-097 "NOSI regarding Availability of Admin Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences

Notice Number: NOT-HL-20-801

The purpose of this Notice is to inform potential applicants that NHLBI’s participation in NOT-MH-20-053 “Notice of Special Interest (NOSI): Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19” will cease on July 31, 2020. An application submitted in response to NOT-MH-20-053 that is intended for NHLBI and received on August 01, 2020 or later will be withdrawn.

More Information

NOT-HL-20-799 - National Heart, Lung, and Blood Institute- Notice of NHLBI Participation in NOT-OD-20-097 "Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences"

Notice Number: NOT-HL-20-799

The purpose of this Notice is to inform potential applicants that NHLBI’s participation in NOT-OD-20-097 “Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences” will cease on July 31, 2020. An application submitted in response to NOT-OD-20-097 that is intended for NHLBI and received on August 01, 2020 or later will be withdrawn.

More Information

NOT-AG-20-036 - Notice of NIA Participation in PA-20-135, "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"

Notice Number: NOT-AG-20-036

This Notice informs potential applicants that the National Institute on Aging (NIA) will participate, effective immediately, in PA-20-135, “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional).”

More Information

NOT-DA-20-061 - Notice of NIDA Participation in PA-20-135, "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"

Notice Number: NOT-DA-20-061

The purpose of this Notice is to inform potential applicants that the National institute of Drug Abuse (NIDA) will participate, effective immediately, in PA-20-135, “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)”.

More Information

NOT-DC-20-010 - Notice of NIDCD's Participation in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"

Notice Number: NOT-DC-20-010

The purpose of this Notice to inform potential applicants that the National Institute on Deafness and Other Communication Disorders (NIDCD) will participate, effective immediately, in PA-20-135 “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional).”

More Information

NOT-OD-20-111 - Notice of ORWH Participation in PA-20-135, “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)”

Notice Number: NOT-OD-20-111

The purpose of this Notice is to inform potential applicants that the Office of Research on Women’s Health (ORWH) will participate, effective immediately, in PA-20-135 “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)”.

More Information

NOT-MH-20-064 - Notice of NIMH Participation in PA-20-135, "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"

Notice Number: NOT-MH-20-064

The purpose of this Notice is to inform potential applicants that the National Institute of Mental Health (NIMH) will participate, effective immediately, in PA-20-135, “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)”.

More Information

NOT-DK-20-026 - Notice of Additional Activity Code Accepted for "NOT-DK-20-018, Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIDDK"

Notice Number: NOT-DK-20-026

The purpose of this Notice is to add the U24 activity code to the activity codes eligible for submissions and adjust the language for parent awards to be eligible under NOT-DK-20-018: Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIDDK.

More Information

NOT-AA-20-007 - Notice of Participation of NIAAA in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional"

Notice Number: NOT-AA-20-007

The purpose of this Notice is to inform applicants that the National Institute on Alcohol Abuse and Alcoholism (NIAAA) will participate, effective immediately, in PA-20-135 “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)”.

More Information

NOT-CA-20-048 - Notice of National Cancer Institute (NCI) Participation in PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)

Notice Number: NOT-CA-20-048

The purpose of this Notice is to inform potential applicants that the National Cancer Institute (NCI) is participating, effective immediately, in PA-18-935, “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional).”

More Information

NOT-DC-20-003 - Notice of NIDCD's Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)"

Notice Number: NOT-DC-20-003

The purpose of this Notice is to inform applicants that the National Institute on Deafness and Other Communication Disorders (NIDCD) will participate, effective immediately, in PA-18-935 “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional)”. The following changes and updates are made to PA-18-935 (shown in italics) to reflect NIDCD’s participation in this funding opportunity announcement (FOA).

More Information

NOT-HG-20-034 - Notice of NHGRIs Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)"

Notice Number: NOT-HG-20-034

The purpose of this Notice is to inform applicants that the National Human Genome Research Institute (NHGRI) will participate, effective immediately, in PA-18-935 “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional)”.

More Information

NOT-MD-20-018 - Notice of Participation of the National Institute on Minority Health and Health Disparities (NIMHD) in PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)

Notice Number: NOT-MD-20-018

The purpose of this Notice to inform potential applicants that the National Institute on Minority Health and Health Disparities (NIMHD) will participate, effective immediately, in PA-18-935 “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional).”

More Information

NOT-TR-20-015 - Notice of NCATS' Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)"

Notice Number: NOT-TR-20-015

The purpose of this Notice is to inform applicants that the National Center for Advancing Translational Sciences (NCATS) will participate, effective immediately, in PA-18-935 “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional)”.

More Information

Request for Proposal

NOT-CA-20-077 - Request for Proposals (RFP) Solicitation S20-119: Serological Sciences Network Capacity Building Centers

Notice Number: NOT-CA-20-077

Leidos Biomedical Research, Inc. (Leidos Biomed) has issued an RFP for Capacity Building Centers to support the Serological Sciences Network (SeroNet), developed to mobilize collaborative efforts to develop serological assays of high specificity and high sensitivity for deployment to test for SARS-CoV-2 induced immune responses and to rapidly expand national serological testing capacity.

More Information

NIH NOSI (Notice of Special Interest)

NOT-OD-20-097 - National Institutes of Health/DHHS - Notice of Special Interest (NOSI): Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences

Notice Number: NOT-OD-20-097

This Notice of Special Interest (NOSI) highlights the urgent need for social, behavioral, economic, health communication, and epidemiologic research relevant to the 2019 Novel Coronavirus (SARS-CoV-2) and COVID-19. This NOSI encourages urgent competitive supplements and administrative supplements to existing longitudinal studies that address key social and behavioral questions related to the COVID-19 pandemic, including adherence to and transmission mitigation from various containment and mitigation efforts; social, behavioral, and economic impacts from these containment and mitigation efforts; and downstream health impacts resulting from these social, behavioral, and economic impacts,including differences in risk and resiliency based on gender, race and ethnicity, socioeconomic status, and other social determinants of health.

More Information

NOT-TR-21-006 - National Center for Advancing Translational Sciences/NIH/DHHS - Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)

Notice Number: NOT-TR-21-006

NCATS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel coronavirus (SARS-CoV-2) and the disease it causes, i.e., “coronavirus disease 2019” (COVID-19). NCATS is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial.

More Information

NOT-AT-20-011 - Availability of Administrative Supplements and Urgent Competitive Revisions for Research on Stress Management in Relation to Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-AT-20-011

NCCIH is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). Topics of specific interest for this NOSI include research on stress management strategies, including mind and body approaches, that individuals may engage in remotely to address stressors related to social distancing, as well as to address recovery and recurrence of symptoms during and after COVID-19 infections.

When applying please follow the additional instructions in the corresponding NOSI and include the NOSI # as indicated.

More Information

NOT-EB-20-003 - Notice of NIBIB's Participation in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"

Notice Number: NOT-EB-20-003

The purpose of this Notice is to inform applicants that the National Institute of Biomedical Imaging and Bioengineering (NIBIB) will participate, effective immediately, in PA-20-135 “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)”.

When applying please follow the additional instructions in the corresponding NOSI and include the NOSI # as indicated.

More Information

2021 NIH NOSI (Notice of Special Interest)

NOT-MD-21-020 - Notice of Special Interest (NOSI): Administrative Supplements to NIMHD Awards for Research on HIV/AIDS in Populations that Experience Health Disparities (Admin Supp Clinical Trial Optional)

Notice Number: NOT-MD-21-020

NIMHD is soliciting supplements to active NIMHD grants and cooperative agreements to support research on HIV/AIDS in NIH-designated populations that experience health disparities, including Blacks or African Americans, Hispanics or Latinos, American Indians and Alaska Natives, Asian Americans, Native Hawaiians and other Pacific Islanders, socioeconomically disadvantaged populations, underserved rural populations, and sexual and gender minorities. The purpose of this NOSI is to emphasize the continued importance of conducting research on HIV/AIDS that will further the EHE effort, including but not limited to research on how the COVID-19 pandemic and structural racism and discrimination affect HIV risk, prevention, and treatment among populations that experience health disparities.

Release Date: July 6, 2020

More Information

NOT-AI-20-058 - Notice of Early Expiration of "Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)”

Notice Number: NOT-AI-20-058

The purpose of this Notice is to inform the extramural community that NOT-AI-20-034, “Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)” is rescinded effective immediately. NOT-AI-20-034 is replaced by NOT-AI-20-059 which highlights very specific needs for competitive revision applications to NIAID grants to facilitate the Federal SARS-CoV-2/COVID-19 research response.

Release Date: July 6, 2020

More Information

07/02/2021 - NOT-AI-20-059 - National Institute of Allergy and Infectious Diseases/NIH/DHHS - Notice of Special Interest (NOSI): Emergency Competitive Revisions for Select Research Activities related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

NIAID is issuing this Notice of Special Interest (NOSI) to highlight very specific and limited needs for Competitive Revision applications to active NIAID grants in order to further build the infrastructure that NIAID needs to support the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) research response. This NOSI replaces NOT-AI-20-034 which was rescinded with this issuance of this Notice.

Expiration Deadline: July 2, 2021

More Information

07/10/2021 - NOT-TR-20-011: Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need

Notice Number: NOT-TR-20-011

National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel Coronavirus (COVID-19). NCATS is particularly interested in projects focusing on the use of informatics solutions to diagnose cases and the use of CTSA-supported core resources (e.g., advanced scientific instruments, highly-specialized facilities, and regulatory expertise) to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

First Available Due Date: May 04, 2020
Expiration Date: July 10, 2021

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

07/12/2021 to 07/0/2023 - NOT-FD-21-014 - Notice of Special Interest (NOSI): Add COVID-19 Capacity Building Grants to PAR-18-604 Vet-LIRN Network Capacity-Building Projects (Vet-LIRN)

Notice Number: NOT-FD-21-014

The purpose of this notice is to inform potential applicants to the Veterinary Laboratory Investigation and Response Network (Vet-LIRN), about a special interest in applications focusing on COVID-19 animal diagnostics.

Deadlines: 12-Jul-2021 , 11-Jul-2022 , 10-Jul-2023

More Information

07/13/2021 - NOT-OD-20-129 - Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) in Individuals with Down Syndrome for the INCLUDE Project

Notice Number: NOT-OD-20-129

NIH is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) in individuals with Down syndrome in conjunction with the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project. Because many people with Down syndrome are at increased risk of having co-occurring medical conditions, such as pulmonary disease, cardiac problems, obesity, diabetes, sleep apnea, and altered immune function that may predispose them to more severe infection with SARS-CoV-2, they may be particularly vulnerable to COVID-19 complications. Combined with shared living situations, and reduced access to testing and treatment services due to disparities in provision of resources, the impact of COVID-19 infection in people with Down syndrome is likely to be elevated. The overarching goal of this NOSI is to improve understanding and treatment of COVID-19 infection in individuals with Down syndrome and reduce COVID-19 associated morbidity and mortality for this population, which may be disproportionately affected by, have higher infection rates of, and/or be at elevated risk for adverse outcomes from contracting the virus.

More Information

08/10/2021 to 06/05/2024 - NOT-OD-21-100 - National Institutes of Health/DHHS - Notice of Special Interest (NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health

This Notice of Special Interest (NOSI) is being issued by the NIH Adherence Network through the Office of Behavioral and Social Sciences Research (OBSSR) with participation from multiple NIH Institutes, Centers, and Offices. This NOSI calls for research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider, healthcare system, and community levels. The specific research interests of participating NIH Institutes and Centers are detailed within.

Deadlines
10-Aug-2021 , 07-Sep-2021 , 05-Oct-2021 , 15-Oct-2021 , 16-Oct-2021 , 14-Dec-2021 , 07-Jan-2022 , 05-Feb-2022 , 15-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 15-Jun-2022 , 16-Jun-2022 , 10-Aug-2022 , 07-Sep-2022 , 05-Oct-2022 , 14-Oct-2022 , 16-Oct-2022 , 14-Dec-2022 , 07-Jan-2023 , 05-Feb-2023 , 15-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 15-Jun-2023 , 16-Jun-2023 , 10-Aug-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 17-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024

More Information

09/07/2021 to 05/07/2024 - NOT-HD-21-026 - Notice of Special Interest (NOSI): Research on the Impact of the Covid 19 Pandemic and Risks for Abuse and Injury Among Vulnerable Children and Youth

Pre-existing disparities and apparent challenges in resources for treatment and care of children experiencing abuse call for more data and research resources to identify, substantiate and improve care and ultimately outcomes for vulnerable children and youth during and following the current crisis. It is anticipated that research stemming from this NOSI will help to provide greater recognition of the need for better resources and support for vulnerable children. More touchpoints for communication, identification and screening for risks of child trauma, and injury will help inform processes for screening, identification, treatment and care in new and emerging disaster related contexts in the future.

Application Deadlines: 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024

More Information

09/07/2021 to 09/07/2024 - NOT-AA-21-028 - Notice of Special Interest (NOSI): Public Policy Effects on Alcohol-, Cannabis-, Tobacco-, and Other Drug-Related Behaviors and Outcomes

This announcement encourages applications to conduct research on the effects of public policies on health-related behaviors and outcomes associated with alcohol, cannabis, tobacco, prescription drugs, and other substances. The purpose of the Notice is to advance understanding of how public policy may serve as a tool for improving public health and welfare through its effects on behaviors and outcomes pertaining to alcohol and other drugs. This Notice is intended to support innovative research to examine policy effects that have the potential to lead to meaningful changes in public health. Research projects that may be supported include, but are not necessarily limited to: causal analyses of the effects of one or multiple public policies; evaluations of the effectiveness of specific public policies as tools for improving public health through their effects on alcohol-, cannabis-, tobacco-, and other substance-related behaviors and outcomes; studies of disparities in policy effects and the role of policy in exacerbating or potentially reducing health disparities; and research to advance methods and measurement used in studying relationships between public policies and alcohol-, cannabis-, tobacco-, and other substance-related behaviors and outcomes.

Application Deadlines: 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024

More Information

09/07/2021 to 01/27/2022 - NOT-MD-21-008 - Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities

This Notice of Special Interest (NOSI) highlights the need for research strategies and interventions to address vaccine hesitancy, uptake, and implementation among populations who experience health disparities in the US.* Research is needed to understand and address misinformation, distrust, and hesitancy regarding vaccines (e.g., SARS-CoV-2, pneumococcal, influenza, hepatitis B, human papilloma virus (HPV), and herpes zoster) among adults in the United States and territories, especially in populations at increased risk for morbidity and mortality due to long-standing systemic health and social inequities and chronic medical conditions. The purpose of this NOSI is to solicit community-engaged research to: 1) evaluate intervention strategies (e.g., expand reach, access) to facilitate vaccination uptake in clinical and community contexts; and 2) address the barriers to increasing reach, access, and uptake of vaccinations among health disparity populations at high risk and likely to experience vaccine hesitancy.

Application Deadlines: 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022

More Information

09/07/2021 to 09/07/2024 - NOT-DA-20-084 - National Institute on Drug Abuse/NIH/DHHS - Notice of Special Interest (NOSI): Effects of Smoking and Vaping on the Risk and Outcome of COVID-19 Infection

The purpose of this notice is to communicate NIDA’s interest in supporting research on the effects of smoking or vaping tobacco or marijuana on the risk of acquiring COVID-19 and the clinical course of the infection.

Deadlines
07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024

More Information

09/07/2021 to 06/05/2024 - National Institutes of Health/DHHS - Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)

The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants of the special interest of NHLBI in research to understand host resilience as a critical determinant of outcomes in acute respiratory distress syndrome (ARDS) /acute lung injury (ALI).

Deadlines
07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024

More Information

09/07/2021 to 09/07/2024 - NOT-DA-21-011 - Notice of Special Interest (NOSI): Effects of Smoking and Vaping on the Risk and Outcome of COVID-19 Infection

Notice Number: NOT-HD-20-021

The purpose of this notice is to communicate NIDA’s interest in supporting research on the effects of smoking or vaping tobacco or marijuana on the risk of acquiring COVID-19 and the clinical course of the infection. This Notice is a reissuance of NOT-DA-20-084.

Application Deadlines: 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024

More Information

09/07/2021 to 09/07/2024 - NOT-DA-21-001 - National Institute on Drug Abuse/NIH/DHHS - Notice of Special Interest (NOSI): Deciphering the Mosaic of Glia in the Addicted Brain

National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) to inform potential applicants of its interest in research project grant submissions that examine the effects of drug use on the structural and functional diversity and plasticity of glia and non-neuronal cells on nervous system process in the context of drug misuse and substance use disorders (SUD). Glial and other non-neuronal cells include astrocytes, microglia, oligodendrocytes and ependymal cells.

Deadlines: 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 25-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 25-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 25-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 25-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 25-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 25-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 07-Sep-2024

More Information

09/07/2021 to 09/07/2022 - NOT-MH-21-225 - National Institutes of Health/DHHS - Notice of Special Interest (NOSI): COVID-19 Related School Disruptions Impact on Mental Health, Cognitive, Social, and Emotional Development of Children

NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in research to understand the mental health impact of the Coronavirus Disease 2019 (COVID-19) pandemic on school-aged children, specifically ages 3 – 12. Particularly, we are interested in the potential impact of primary instruction settings disruptions (e.g., pre-school, elementary school) on the mental health, cognitive, social, and emotional development of children. Empirical data would aid in balancing health risks for various public health mitigation strategies affecting children in the current pandemic as well as inform how to both be prepared and respond to future public health emergencies, including pandemics and disaster scenarios.

Deadlines: 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022

More Information

09/07/2021 to 09/07/2023 - NOT-MH-21-230 - National Institutes of Health/DHHS - Notice of Special Interest (NOSI): Research on Strategies to Enhance Mental Health Interventions and Services within Employment and Job Training Settings

The purpose of this Notice of Special Interest (NOSI) is to encourage research focused on detection and intervention to prevent or treat mental health concerns, symptoms or disorders including drug-related conditions among unemployed and underemployed people participating in employment programs and job training settings (referred to here as “employment service customers” or “customers”). Considering the COVID-19 pandemic, the sharp rise and potentially long duration of unemployment raises concerns about the development and worsening of mental health symptoms and disorders, drug use behaviors, and suicide risk and necessitates further research to confirm the efficacy or demonstrate effectiveness of strategies in this area.

Deadlines: 07-Sep-2021 , 05-Oct-2021 , 15-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 15-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 15-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 14-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 15-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 15-Jun-2023 , 16-Jun-2023 , 07-Sep-2023

More Information

10/05/2021 to 06/16/2023 - NOT-HD-20-021 - National Institute of Child Health and Human Development/NIH/DHHS - Notice of Special Interest (NOSI): Emerging Viral Infections and their Impact on the Male and Female Reproductive Tract

Notice Number: NOT-HD-20-021

Submission Dates: 05-Oct-2021 , 16-Oct-2021 , 05-Feb-2022 , 16-Feb-2022 , 05-Jun-2022 , 16-Jun-2022 , 05-Oct-2022 , 16-Oct-2022 , 05-Feb-2023 , 16-Feb-2023 , 05-Jun-2023 , 16-Jun-2023

The purpose of this Notice is to invite applications proposing cutting-edge research on emerging viral infections that are thought to primarily impact non-reproductive sites, at least at initial presentation, but may also affect the male and/or female reproductive tract. The recent global outbreak of the novel coronavirus, SARS-CoV-2, is not an anomaly and will most likely not be the last virus occurrence. Today, infectious diseases are emerging and reemerging more quickly than ever before. In the last four-five years alone, two viral infections, one caused by the Zika virus (ZIKV) and the other caused by a SARS-CoV-2 (Covid19), have spread world-wide, resulting in death, severe disease with yet, unknown, long-term morbidities., or severe birth defects to the new-born. Both ZIKV and SARS-CoV-2 infections may affect male and/or female reproductive systems in addition to other non-reproductive sites. Therefore, it becomes essential to investigate possible effects of emerging viruses on reproductive tissues and cells to better understand potential impacts on fertility that may be sex specific.

More Information

2022 NIH NOSI (Notice of Special Interest)

01/26/2022 - NOT-TR-20-016 - Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus

Notice Number: NOT-TR-20-016

NCATS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the COVID-19. NCATS is especially interested in research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

Expiration Date: January 26, 2022

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

01/26/2022 - NOT-TR-20-017 - Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus

Notice Number: NOT-TR-20-017

NCATS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the COVID-19. NCATS is especially interested in research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

Expiration Date: January 26, 2022

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

03/31/2022 - NOT-DA-21-041 - National Institute on Drug Abuse/NIH/DHHS - Notice of Special Interest (NOSI): Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus

Notice Number: NOT-DA-21-041

NIDA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for continued research on the impacts of SARS-CoV-2, the coronavirus that causes COVID-19. NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders

Expiration Date: March 31, 2022

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

09/08/2022 - NOT-DC-20-008 - Notice of Special Interest (NOSI): NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders

Notice Number: NOT-DC-20-008

Coronavirus Disease 2019 (COVID-19) is a recently emerged human disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There is a paucity of data on the impact of SARS-CoV-2 on the sensory and communicative functions within the scientific mission areas of NIDCD. NIDCD invites applications for research on COVID-19 in relation to NIDCD’s scientific programs of hearing, balance, taste, smell, voice, speech and language (HBTSVSL). Given the early stage of COVID-19 research, it is critical that there is a strong premise for research proposals submitted in response to this NOSI. When appropriate, NIDCD encourages multi-disciplinary approaches to move the research beyond in vitro and animal models.

Expiration Date: Sept 8, 2022

More Information

2023 NIH NOSI (Notice of Special Interest)

01/08/2023 - NOT-AI-21-008 - Notice of Special Interest (NOSI): Complement in Basic Immunology (CIBI)

Notice Number: NOT-AI-21-008

NIAID conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious diseases, including fundamental immunology research that aims to understand the complex interactions between pathogens and their human hosts and generate the knowledge essential for developing safe and effective treatments and vaccines. The mechanisms by which complement influences immune responses have been under appreciated, and a better understanding of complement action will inform high priority adjuvant and vaccine development, and also shed light on the pathogenesis of infections such as SARS CoV-2.

Release Date: February 4, 2021
First Available Due Date: June 5, 2021
Expiration Date: January 8, 2023

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

03/15/2023 - NOT-HS-21-010 - Agency for Healthcare Research and Quality/DHHS - Special Emphasis Notice (SEN): AHRQ Announces Interest in Health Services Research to Address Substance Use Disorder Epidemic

Notice Number: NOT-HS-21-010

The purpose of this Special Emphasis Notice (SEN) is to inform the research community that the Agency for Healthcare Research and Quality is interested in receiving health services research grant applications to advance our nation’s understanding of the substance use disorder crisis and provide solutions for addressing it.

More Information

04/02/2023 - NOT-MH-20-040 - NIMH Administrative Supplement Program to Enable Continuity of Research Experiences of MD/PhDs during Clinical Training (Admin Supp Clinical Trial Optional)

Notice Number: NOT-MH-20-040

The purpose of the NIMH Administrative Supplement Program to Enable Continuity of Research Experiences of MD/PhDs during Clinical Training is to support advanced research opportunities for exceptional individuals holding the MD/PhD degree who are early in their research careers and thereby help these individuals transition efficiently and effectively from the period of clinical training to the next stage of their research careers. This administrative supplement program will provide focused, protected research time for eligible individuals during residency and/or clinical fellowship. The proposed research experience must have the potential to contribute significantly to the candidate’s research career.

Release Date: April 14, 2020
First Available Due Date: April 01, 2021
Expiration Date: April 02, 2023

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

05/08/2023 - Notice of Special Interest (NOSI): Aging-Relevant Behavioral and Social Research on Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-AG-21-015

Release Date: January 26, 2021
First Available Due Date: March 04, 2021
Expiration Date: May 08, 2023

NIA is issuing this Notice of Special Interest (NOSI) to highlight the continuing need for behavioral, psychological, social, and economic research on SARS-CoV-2 and coronavirus disease 2019 (COVID-19). There is a need for ongoing research on the longer-term effects of COVID-19 on the health and well-being of those infected, those caring for the sick, and many others whose lives were disrupted by the pandemic and its associated mitigation and prevention strategies. Beyond effects on individuals, this pandemic has brought about unprecedented social and economic disruption that is expected to have long-term and profound effects on the health of the population. These effects will likely be particularly acute for NIH-designated health disparity populations, and other COVID-19 vulnerable groups including older adults, who have experienced higher rates of COVID-19 infection, who in some cases rely on the efforts of paid and unpaid care partners, and who may have additional barriers to accessing the medical system itself. Further, middle-aged and older frontline healthcare and essential workers and their families face unique risks of exposure to both infection and other health-related outcomes by virtue of their employment.

More Information

05/08/2023 - Notice of Special Interest (NOSI): NIDCR Support for Research on the Physiological Involvement of Oral Cavity in Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-DE-21-001

Release Date: January 26, 2021
First Available Due Date: June 05, 2021
Expiration Date: May 08, 2023

The National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to encourage research studies focused on the physiological involvement of oral cavity and oral manifestations related to SARS-CoV-2 and/or Coronavirus Disease 2019 (COVID-19).

More Information

2024 NIH NOSI (Notice of Special Interest)

01/28/2024 - NOT-DA-20-058 - Notice of Special Interest (NOSI): Utilizing Telemedicine or Other Remote-Based Platforms to Develop and Support Treatments for Substance Use Disorders

Notice Number: NOT-DA-20-058

There is an urgent need for remotely delivered Substance Use Disorder (SUD) treatments to reduce patient burden and for methods to conduct clinical trials remotely. The purpose of this NOSI is to stimulate research to evaluate the safety and efficacy of telemedicine or remotely provided treatments for SUD, and to develop tools for remote collection of data in clinical trials of treatments for SUD.

Release Date: June 29, 2020
First Available Due Date: October 05, 2020
Expiration Date: January 08, 2024

More Information

09/08/2024 - NOT-DA-21-017 - Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19

Notice Number: NOT-DA-21-017

NIDA is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19.

Release Date: February 4, 2021
First Available Due Date: May 5, 2021
Expiration Date: September 08, 2024

More Information

09/08/2024 - NOT-DA-21-018 - Notice of Special Interest (NOSI): Long-Term Neurocognitive Consequences of COVID-19 in Individuals Living with HIV and Substance Use Disorders

Notice Number: NOT-DA-21-018

NIDA is interested in receiving research applications focusing on studying the long-term neurocognitive consequences of the COVID-19/HIV/SUDs syndemic.

Release Date: February 3, 2021
First Available Due Date: May 7, 2021
Expiration Date: September 8, 2024

More Information

Continuous Submission

AIDS United - Relief, Recovery and Resilience Fund

AIDS United is making funds available, through this request for applications, to assist in meeting the needs of organizations serving people living with and at risk for HIV and AIDS, and that are experiencing challenges meeting their community’s needs because of the COVID-19 pandemic.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Adira Foundation - Fast-Track Grant Response: COVID-19

As people all over the world are joining together to slow the spread of the coronavirus and its impact on daily life—an effort that changes daily and differs city to city and state to state—Adira Foundation is redirecting some funding to meet immediate and pressing need in our community.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

American College of Chest Physicians - CHEST Foundation COVID-19 Community-based Grant

As the charitable foundation for the American College of Chest Physicians, the CHEST Foundation has a mission of championing lung health by supporting clinical research, patient education, and community service. During this time of need, the CHEST Foundation is focusing efforts on assisting those making a difference in their communities during the COVID-19 pandemic.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Biogen - COVID-19 Response Program

The Biogen Foundation has committed $10M to aid in COVID-19 relief efforts around the world. At this time, the Biogen Foundation’s COVID-19 relief efforts are focused on the following categories: expanding and ensuring access to testing; easing the burden on healthcare systems and healthcare workers; and providing food and necessities for our most vulnerable populations.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Bloomberg Philanthropies - Coronavirus Local Response Initiative

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Brookhaven National Laboratory - COVID-19 Research Support

The Center for Biomolecular Structure team is supporting remote macromolecular crystallography experiments at Beamlines 17-ID-1 (AMX) and 17-ID-2 (FMX) for research projects related to COVID-19.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Brooklyn Community Foundation - Brooklyn COVID-19 Response Fund

Funding Amount: $10,000

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Call for Expert Collaborators: COVID-19 Response

Crowdhelix is seeking researchers & innovators worldwide with a strong track record of excellence in fields relevant to the global effort to tackle the novel coronavirus (COVID-19) pandemic. The sponsor is offering free access to Crowdhelix, their online Open Innovation platform, to experts seeking to collaborate across continents and disciplines in developing R&D funding proposals to help tackle COVID-19.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Coalition for Epidemic Preparedness Innovations (CEPI) - CEPI partner NIBSC - Partners for Sourcing Serum or Plasma from Individuals Recovered from Infection with SARS-CoV-2 Variants for the Development of Antibody Working Standards and Reference Panels

Through a joint effort in 2020, the Coalition for Epidemic Preparedness Innovations (CEPI), the National Institute for Biological Standards and Control (NIBSC), and the World Health Organization (WHO) provided COVID-19 vaccine developers and the entire scientific community with a research reagent for an anti-SARS-CoV-2 antibody, an International Reference Panel and the first WHO International Antibody Standard for assay calibration. These materials are constituted of plasma samples sourced from SARS-CoV-2 convalescent patients.

More Information

COVID-19 Early Treatment Fund (CETF) - Grants Program

CETF will be funding initiatives that focus on treating outpatients with COVID-19 to prevent hospitalization. Grant recipients are required to share what they learn with others.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

COVID-19 Fast Track Access

To facilitate research on COVID-19, CERIC has set up a dedicated Fast Track Access to a selected number of instruments including 600 and 800 MHz NMR, SAXS light scattering laboratory, Cryo EM, synchotron beamlines for Small Angle X-ray scattering and X-ray diffraction, and Synchroton Infrared Source for Spectroscopy and Imagine. Due to the travel restrictions in place for several countries, remote access will be preferred.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

COVID-19 HPC Consortium

The COVID-19 HPC Consortium encompasses computing capabilities from some of the most powerful and advanced computers in the world. XSEDE hopes to empower researchers around the world to accelerate understanding of the COVID-19 virus and the development of treatments and vaccines to help address infections. Consortium members manage a range of computing capabilities that span from small clusters to some of the very largest supercomputers in the world.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

COVID-19 Relief Fund

Robin Hood anticipates making grants to 501(c)(3) organizations in New York City that are well-positioned to serve low-income communities. The initial grants, expected to last three months in duration, will average $45,000.

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Diamond Light Source - Rapid Access Call for Proposals: SARS-CoV-2

As part of Diamond’s effort to combat COVID-19 (as demonstrated by the fragment screening campaign against SAR-CoV-2 Main protease), fragment screening expertise and infrastructure are offered to users working on Covid-19 related projects.

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

John (Elton) AIDS Foundation - COVID-19 Emergency Fund

The Elton John AIDS Foundation has launched the COVID-19 Emergency Fund to support organisations to mitigate the adverse effects of the COVID-19 pandemic on HIV response efforts for key population communities around the world.

More Information

European Synchrotron Radiation Facility - Covid-19 Scientific Research

The ESRF is ready to provide access to its facilities for Covid-19 related research projects. This exceptional access will be granted with the aim to contribute to the international scientific effort to overcome the covid-19 pandemic.

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Euro-Bioimaging - Fast Track Access to Biological and Biomedical Imaging Technologies for COVID-19 Research Projects

This opportunity offers access to biomedical imaging technologies to to scientists who have COVID-19 related research projects that need imaging resources.

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

European Synchrotron Radiation Facility - Mail-in Protein-to-Structure Services to Support Structural Biology Research Related to COVID-19 at the EMBL Grenoble HTX Lab and the Joint ESRF-EMBL MX Beamlines

The ESRF-EMBL Joint Structural Biology Group (JSBG) invite COVID-19 related proposals that can benefit from the seamless integration of the EMBL High throughput Crystallization Facility (HTX Lab) with the highly automated JSBG MX beamlines at the ESRF. The pipeline starts with mail-in samples and integrates crystallization screening, crystal optimization, ligand soaking if required and eventually fragment screening with libraries of up to 1200 fragments. Crystals obtained will be automatically harvested and passed to the ESRF for automated X-ray data collection, with real-time access to experimental results and parameters. This pipeline is uniquely suited to support of structural biology projects in conditions of confinement and restricted access to labs. The HTX lab is already accepting crystallization projects on COVID-19 related research and three ESRF beamlines (MASSIF-1 (ID30A-1), ID30B and ID23-2) will become operational after 11 May 2020.

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Extreme Science and Engineering Discovery Environment (XSEDE) - COVID-19 HPC Consortium

The COVID-19 HPC Consortium encompasses computing capabilities from some of the most powerful and advanced computers in the world. XSEDE hopes to empower researchers around the world to accelerate understanding of the COVID-19 virus and the development of treatments and vaccines to help address infections. Consortium members manage a range of computing capabilities that span from small clusters to some of the very largest supercomputers in the world.

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Fast Grants

Emergent Ventures invites applications from scientists at academic institutions currently working on a COVID-19 related project and in need of funding. Fast Grants are $10,000 to $500,000 and decisions are made in under 48 hours.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Federal Communications Commission - COVID-19 Telehealth Program

The COVID-19 Telehealth Program will provide $200 million in funding, appropriated by Congress as part of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, to help health care providers provide connected care services to patients at their homes or mobile locations in response to the novel Coronavirus 2019 disease (COVID-19) pandemic.

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Funeral Services Foundation - COVID-19 Crisis Response Fund

This fund is designed to be flexible and will provide grants for immediate needs including funeral service emergency response to significant loss of life, to organizations and resources providing service to families with unresolved and complicated grief due to loss during this crisis, and for other important needs of the funeral service profession and the families served. The Fund will consider proposals from US 501(c)3 nonprofit organizations and Canadian registered charities.

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Ginkgo Bioworks - Access to Platform for Partner COVID-19 Projects

Ginkgo Bioworks has committed its platform to supporting research and development efforts for COVID-19, including $25M of free access to its infrastructure.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Global Innovation Fund Grant Program

The Global Innovation Fund was set up to confront global development challenges by funding innovations with the potential to improve the lives of the world’s poorest people. GIF will devote resources to new deals for COVID-19-related grantmaking in 2020.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

ICESCO prize for Fighting against Coronavirus

In response to the World Health Organization’s appeal to the international community to “seize every opportunity to curb, contain, combat, and delay the spread of the virus, and mitigate its impact”, the Islamic World Education, Scientific, and Cultural Organization (ICESCO) announces its Prize for Fighting Novel Coronavirus (COVID-19). The amount of the prize is US$200,000, including an award medal.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Innovations for Poverty Action - Competitive Fund for Peace and Recovery

Submission Deadline Not Posted

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Jacob and Valeria Langeloth Foundation - COVID-19 Rapid Response Fund

The Jacob and Valeria Langeloth Foundation created the COVID-19 Rapid Response Fund (CRRF) to enable Langeloth to address organizations’ urgent and critical needs that have arisen due to the COVID-19 global pandemic.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Jameel (Abdul Latif) Poverty Action Lab (J-PAL) - J-PAL North America Short Term Research Management Program (STReaM)

Research projects may need to adapt quickly in the context of COVID-19. The Short Term Research Management program (STReaM) makes experienced research management staff available to help researchers in the North America region navigate these challenges. STReaM will continue to accept requests for support through its regular application process. The team can offer hands-on support to help think through challenging obstacles, such as impacts to timelines, adapting to virtual research methods, and navigating difficult conversations with stakeholders. Researchers conducting projects in the North America region are invited to request this support, regardless of the project phase.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Jameel (Abdul Latif) Poverty Action Lab (J-PAL) - J-PAL North America US Health Care Delivery Initiative (HCDI)

As always, HCDI is open to receiving off-cycle proposals on time-sensitive topics. HCDI welcomes proposals that focus on producing evidence that North America decision-makers can act upon promptly to respond to the current crisis. Please note that the sponsor will not accept human subjects research requiring in-person interactions with subjects.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Johnson (Robert Wood) Foundation - Pioneering Ideas: Exploring the Future to Build a Culture of Health

The Pioneer team seeks to anticipate the future, and support unconventional approaches and breakthrough ideas that can help lead the way to a future where everyone in the United States can live their healthiest life possible. The Pioneering Ideas: Exploring the Future to Build a Culture of Health call for proposals (CFP) seeks applications from visionary thinkers across the nation who are doing cutting-edge work to advance health equity.

More Information

National Institute of Allergy and Infectious Diseases/NIH/DHHS - Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed)

The purpose of this public health emergency funding opportunity is to provide Personal Protective Equipment (PPE) to directly support the needs of the NIAID’s vaccine and treatment clinical trials and clinical studies for COVID-19. This program will ensure that adequate protective equipment is available to directly assist in safely carrying out the clinical activities and direct interactions with the patients participating in the trial. Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by NIAID’s emergency appropriation provided by “The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020” and “The Coronavirus Aid, Relief and Economic Security (CARES) Act”.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS - Rapid Acceleration of Diagnostics (RADx): Fast-Track Program for COVID-19 Test Development and Distribution

National Institute of Biomedical Imaging and Bioengineering (NIBIB) is urgently soliciting proposals and can provide up to $500M across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

NIBIB Exploratory/Developmental Research Grant Program (R21 Clinical Trial Optional)

07-May-2020, 16-Jun-2020, 07-Sep-2020, 16-Oct-2020, 07-Jan-2021

National Institute of Biomedical Imaging and Bioengineering (NIBIB) invites applications for exploratory/developmental research programs of interest to the NIBIB (https://www.nibib.nih.gov/research-funding). hese studies are expected to lead to breakthroughs in development of innovative techniques, agents, methodologies, models, or their applications. These studies may involve considerable risk that should be balanced by the potential high impact on human-health and related research. Applicants are expected to propose novel biomedical research approaches for which there is no preliminary data to demonstrate the feasibility of the proposed project. A project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

NIBIB Research Project Grant (R01 Clinical Trial Required)

07-May-2020, 05-Jun-2020, 07-Sep-2020, 05-Oct-2020, 07-Jan-2021

NIH invites applications for discrete, specified, circumscribed projects in areas representing the specific interests and competencies of the investigator(s). This NIBIB Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of the NIBIB. For this Funding Opportunity Announcement, NIBIB will only support R01 applications proposing early-stage clinical trials through Phase I, first-in-human, safety, feasibility or other small clinical trials that inform early-stage technology development. NIBIB will not support applications proposing Phase II, III, IV or pivotal clinical trials or trials in which the primary outcome is efficacy, effectiveness or a post-market concern. This FOA will use the NIH Research Project (R01) award mechanism.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

NIBIB Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)

07-May-2020, 16-Jun-2020, 07-Sep-2020, 16-Oct-2020, 07-Jan-2021, 16-Feb-2021, 07-May-2021, 16-Jun-2021, 07-Sep-2021, 16-Oct-2021, 07-Jan-2022, 16-Feb-2022, 07-May-2022, 16-Jun-2022, 07-Sep-2022, 16-Oct-2022, 07-Jan-2023
This Trailblazer Award is an opportunity for NIH-defined New and Early Stage Investigators (https://grants.nih.gov/policy/early-investigators/index.htm) to pursue research programs of high interest to the NIBIB that integrate engineering and the physical sciences with the life and/or biomedical sciences. A Trailblazer project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. Importantly, applicants must propose research approaches for which there are minimal or no preliminary data.

A distinct feature for this FOA is that no preliminary data are required, expected, or encouraged. However, if available, minimal preliminary data are allowed. Preliminary data are defined as material which the applicant has independently produced and not yet published in a peer-reviewed journal.All preliminary data should be clearly marked and limited to one-half page, which may include one figure. Applications including data more than one-half page or more than one figure will be considered noncompliant with the FOA instructions and will not go forward to review.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)

The NIH Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).

Application Deadlines: 07-May-2020, 16-Jun-2020, 07-Sep-2020, 16-Oct-2020, 07-Jan-2021, 16-Feb-2021, 07-May-2021, 16-Jun-2021, 07-Sep-2021, 16-Oct-2021, 07-Jan-2022

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

Application Deadlines: 07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.   This Funding Opportunity Announcement does not accept applications proposing clinical trial(s

Application Deadlines: 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 05-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

NIH/DHHS - RFA-TR-20-003 -- Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01 Clinical Trial Required)

The purpose of this urgent funding opportunity announcement is to invite applications to repurpose existing therapeutic agents to treat Coronavirus Disease 2019 (COVID-19) sequelae and associated complications that result from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections. The therapeutic agent must have already completed at least a Phase I clinical trial for a different indication, and not require additional regulatory studies for the new indication prior to starting a clinical trial.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

National Science Foundation - Dear Colleague Letter: Sentinel Cells for Surveillance and Response to Emergent Infectious Diseases (Sentinels)

With this Dear Colleague Letter (DCL), the sponsor highlights the interest of existing programs in the Directorate for Biological Sciences (BIO) and the Directorate for Engineering (ENG) in interdisciplinary research for the development of novel biological platforms that are capable of sensing and responding to emerging infectious agents. The mechanism of sensing should be adaptable and or evolvable such that the sentinel cells, or other appropriate biotechnology solutions, are robust to a range of emergent threats, and/or can easily be reprogrammed and deployed once a new threat is identified. The platform’s response should be one or more of the following: alert the user, destroy the threat, protect the host, initiate an immune response or other strategies that would ensure mitigation of the threat. Sentinel cells and organisms that detect and respond to infectious agents with expanding footprints in a host population or expanding host ranges are of particular interest, as the early detection of these infectious agents might have value in preventing future pandemics. In addition, fundamental science and technology that would lead to the development of the envisioned sentinel cells and organisms are also of interest. Investigators are encouraged not to be limited in their approach, but to think broadly about innovations leveraging biology and engineering to advance adaptable detection of emerging biological threats.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Novartis Foundation - COVID-19 Community Response Fund

In response to the COVID-19 pandemic, the Novartis US Foundation has established the US COVID-19 Community Response Fund to support local initiatives and communities in the US impacted by the outbreak. The fund will provide up to USD $5 million over a one-year period for immediate response and recovery efforts related to the pandemic.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Mercatus Center - COVID-19 Response: A Call for Ideas

The Mercatus Center, building on its COVID-19 policy brief series, welcomes proposals for policy briefs, working papers, and articles that address the next round of challenges facing the United States and other countries in the response to the pandemic.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Mozilla Open Source Support (MOSS) Awards Program - COVID-19 Solutions Fund

Mozilla will provide awards of up to $50,000 each to open source technology projects which are responding to the COVID-19 pandemic in some way.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Open Road Alliance - Response to COVID-19

Open Road is offering charitable grants and loans to nonprofits and social enterprises impacted by COVID-19.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Open Call for Innovation Focus Area: COVID-19: Rapid Sanitising Technology

In addition to its regular Open Call, DASA publishes Open Call innovation focus areas to increase awareness of some of the enduring challenges faced by defence and security stakeholders, and to stimulate the submission of relevant innovative proposals.

For the current focus area: COVID-19: Rapid Sanitising Technology, DASA is looking to identify, develop and demonstrate rapid sanitising technologies for ambulances that have transported a patient with suspected COVID-19.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Paung Sie Facility - COVID-19 Prepare and Prevent Grants

These quick impact grants are designed to assist current or former partners to prepare for and conduct activities to build community capacity to prevent and prepare for COVID-19.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Pollination Project - COVID-19 Rapid Response Grants

As of March of 2020, The Pollination Project has redirected all of our focus, support, and seed funding to uplifting the selfless actions of frontline grassroots volunteers working in response to COVID-19 (aka coronavirus) in their communities. Now until it is no longer needed, The Pollination Project will accept applications for volunteer community projects that address: direct needs around water, sanitation, and hygiene; community & emotional resilience; and virtualization of existing grassroots projects.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Pioneering Ideas: Exploring the Future to Build a Culture of Health

The Robert Wood Johnson Foundation (RWJF) has issued a call for proposals, “Pioneering Ideas: Exploring the Future to Build a Culture of Health”, seeking proposals that are primed to influence health equity in the future. They are interested in ideas that address any of these four areas of focus: Future of Evidence; Future of Social Interaction; Future of Food; Future of Work. Additionally, they welcome ideas that might fall outside of these four focus areas, but which offer unique approaches to advancing health equity and our progress toward a Culture of Health.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Priority Access Call for Work on Combating COVID-19

The Paul Scherrer Institute (PSI) has opened a “PRIORITY COVID-19 Call” for short proposals and quick peer review to enable rapid access to beamtime. Research proposals shall have the potential to effectively contribute to the understanding of the COVID-19 virus and/or to improve the clinical or public health response and patient care.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Rapid Access Call for Proposals: SARS-CoV-2

Diamond Light Source are offering priority rapid access for groups who require instrument time for projects directly related to SARS-CoV-2 viral proteins.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Rapid Response Funding for Covid-19

Omidyar Network India has announced a call for proposals for rapid response funding to tackle the challenges posed by the Covid-19 situation and the consequent socio-economic impact. Proposals that strengthen containment, detection and treatment, support crisis management capabilities, and enhance resilience and recovery in the wake of Covid-19 are welcomed. They are committing Rs. 7.5 crore (US $1 million) to this initiative.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

RFA-ES-19-011 -- Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed)

01-May-2020, 01-Jun-2020, 01-Jul-2020, 03-Aug-2020, 01-Sep-2020, 01-Oct-2020, 02-Nov-2020, 01-Dec-2020, 04-Jan-2021, 01-Feb-2021, 01-Mar-2021, 01-Apr-2021, 03-May-2021, 01-Jun-2021, 01-Jul-2021, 02-Aug-2021, 01-Sep-2021, 01-Oct-2021, 01-Nov-2021, 01-Dec-2021, 03-Jan-2022, 01-Feb-2022, 01-Mar-2022, 01-Apr-2022, 02-May-2022, 01-Jun-2022, 01-Jul-2022, 01-Aug-2022, 01-Sep-2022, 03-Oct-2022
This funding opportunity announcement (FOA) is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the FOA is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented.

The shortened timeframe will be achieved by more frequent application due dates and expediting peer review, council concurrence and award issuance. The entire cycle, from submission to award, is expected to be within 3-4 months.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

SARS-COV-2 Diagnostics: Performance Data

FIND is conducting independent evaluations of SARS-CoV-2 molecular tests and immunoassays. To complement these evaluations, and in partnership with WHO in line with the sponsor’s official Collaborating Centre remit, the sponsor is endeavouring to centralize the collection of SARS-CoV-2 diagnostic performance data as a global public good. FIND is working closely with partners including the World Health Organization (WHO) in support of the global effort to combat the COVID-19 pandemic. In this respect, FIND is curating the overall diagnostic pipeline and tracking reported global diagnostic use, as well as conducting independent evaluations of SARS-CoV-2 molecular tests and immunoassays.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Seventh Generation Fund - Flicker Fund

The Flicker Fund was created as a way to rapidly respond to stressed Indigenous communities on the frontlines of COVID-19. The Fund launched within days of learning about the pervasiveness of the virus and its impact on Indigenous communities.

More Information

Social Science Research Council - Just Tech Covid-19 Rapid-Response Grants

The Social Science Research Council (SSRC), as part of its Just Tech program, seeks proposals from across the social sciences and related fields that address the risks, opportunities, and challenges posed by public health surveillance stemming from the Covid-19 pandemic. The sponsor specifically encourages proposals that interrogate the role the public and private sectors may play in mitigating or exacerbating the health crisis, the effects of which are already unevenly distributed.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Staunton Farm Foundation - Emergency Fund for the COVID19 Pandemic

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

TechWatch Meeting Request

The U.S. government, in response to the COVID-19 outbreak, seeks information from stakeholders on available medical countermeasures in development. We are particularly interested in products and technologies that have progressed into or beyond non-clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform. Information regarding diagnostics, therapeutics, vaccines, and other products or technologies relevant to addressing this outbreak are sought.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Turkish Philanthropy Funds - TPF COVID-19 Community Relief Fund

The sponsor has created the COVID-19 Community Relief Fund to support containment, response and recovery activities for those affected and for the responders.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Wellcome Trust - Epidemic Preparedness: COVID-19 Funding Call

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

West Coast Consortium for Technology & Innovation in Pediatrics - 2020 COVID-19 FlexGrants

The West Coast Consortium for Technology & Innovation in Pediatrics (CTIP) is announcing a limited grant opportunity to support pediatric medical device innovators who are able to use their technology to aid in the current COVID-19 pandemic. Companies will be awarded grants up to $15,000 to support activities that apply or adapt their existing medical device to help manage the health impacts of the crisis on children. Medical devices with adult indications that are expanding or wish to expand their clinical indication to pediatrics are welcome to apply.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

June 2021 Application Deadlines

06/21/2021 - Bureau of Land Management/Departme nt of the Interior - Department of the Interior - Bureau of Land Management, Colorado State Office, Expanding Partnerships for Recreation and Visitor Services

The Bureau of Land Management’s Recreation and Visitor Services Program provides a wide variety of recreational opportunities that benefit the public and local communities. The program is also responsible for implementing Administration and Department priorities, including projects to improve racial equity, diversity and inclusion; help strengthen the U.S. economy; minimize the risk and spread of COVID-19; and reduce impacts to the environment and climate. Funding ranges from $5,000 to $50,000.

Application Deadlines: June 21, 2021

More Information

06/21/2021 - U.S. Agency for International Development - USAID/Ghana Accelerating Social and Behavior Change Activity

The purpose of the USAID/Ghana Accelerating Social and Behavior Change activity is to increase and sustain the adoption of healthy behaviors and practices for improved health outcomes with a focus on family planning/reproductive health (FP/RH); malaria prevention and treatment; maternal, newborn, and child health; community and household level water, sanitation and hygiene (WASH) practices; nutrition; and public health emergencies such as COVID-19.

Application Deadlines: June 21, 2021

More Information

06/22/2021 - Doris Duke Charitable Foundation: COVID-19 Fund to Retain Clinical Scientists

Deadline: LOI due June 22, 2021

Amount/Duration: Up to $500,000, plus 10 percent in indirect costs over two years in support of approximately ten to fifteen research supplements of between $30,000 and $50,000 each

Eligibility:

  • Applicants must be recognized by the U.S. Internal Revenue Service as tax-exempt under section 501(c)(3) of the Internal Revenue Code and are not a private foundation or a Type III supporting organization as defined in Section 509(a) of the Code. Schools with existing “extra hands” programs are eligible to apply if they can justify the need for additional — not replacement — support
  • Researchers must hold an MD, DO, PhD, or foreign equivalent degree from an accredited institution. Many of the grants have been earmarked to support institutional programs providing research supplements for physician-scientists.

About: The Fund to Retain Clinical Scientists, is offering a one-time grant to U.S. medical schools that are working to strengthen policies, practices, and processes in support of their research productivity and to retrain early-career faculty with family caregiving responsibilities, with an emphasis on physician scientists’ research on recovery from the impacts of COVID-19. Each grant will provide funding for research supplements to be awarded to eligible faculty and support promising research by early-career faculty whose productivity is challenged.

Link: covid-19-frcs-rfa.pdf (ddcf.org)

06/23/2021 - Health Resources & Services Administration: Rural Health Clinic Vaccine Confidence Program

The Rural Health Clinic Vaccine Confidence (RHCVC) Program is an initiative to improve vaccine confidence, counter vaccine hesitancy, and help with access to vaccination in rural communities that are medically underserved and/or experiencing low COVID-19 vaccination rates. The RHCVC Program will allow Rural Health Clinics (RHCs) to use the funding for a broad range of efforts to improve health care in rural areas and reinforce basic messages about prevention and treatment of COVID-19 and other infectious diseases. Implementation efforts in rural communities may include, but are not limited to: vaccine promotion, information dissemination to rural residents about how and where to get vaccinated, coordinating with existing vaccination sites and public health partners to identify isolated and/or vaccine hesitate populations and increased rural community and individual patient literacy on benefits of broad vaccination and the safety of vaccines. Because RHCs are trusted messengers in rural communities and provide consistent, fact-based public health messaging, the RHCVC Program will help rural communities make informed decisions about their health and COVID-19, including steps to protect themselves and their communities. People living in rural communities will be provided with vaccine education and help with access to vaccination, towards increasing vaccine uptake. This will improve health care in rural areas and reinforce basic messages about the prevention of COVID-19 and other infectious diseases.

The anticipated total available funding for this opportunity is $100,000,000 with an anticipated award amount of approximately $50,000 per RHC site, depending on the number of RHC applicants. HRSA will award grants to all eligible RHCs that submit an acceptable and fundable application for a period of 1 year (July 1, 2021, through June 30, 2022).

There is no cost-sharing for this opportunity. Eligible applicants include Medicare-certified Rural Health Clinics and organizations that own and operate Medicare-certified Rural Health Clinics. Organizations that own and operate multiple RHCs should submit one application that includes all participating RHCs.

Application Deadline: June 23, 2021

More Information

06/25/2021 - Telehealth Technology-Enabled Learning Program

The Health Resources and Services Administration (HRSA) is accepting applications for the fiscal year (FY) 2021 Telehealth Technology-Enabled Learning Program (TTELP). The purpose of this program is to connect specialists at academic medical centers with primary care providers in rural, frontier, and underserved populations, providing evidence-based training and support to help them treat patients with complex conditions in their communities. The TTELP will facilitate learning community models of professional education and support that are adaptable to rural and underserved populations

Application Deadline: June 25, 2021

More Information

July 2021 Application Deadlines

07/05/2021 - Health Care Cost Trends 2021 Digital Health

The Health Care Cost Trends Program Steering Committee (HCCT PSC) is continuing its search for 2021 research projects with a new RFP. In 2019, the SOA formed its Health Care Cost Trends Strategic Research Program to conduct Health Care research. With the emergence of the COVID-19 pandemic, we have seen a shift in health care delivery away from in-person transactions to a more digital form of transactions, including telehealth, e-mails, remote patient monitoring and other
forms of communication. This shift may cause numerous effects and counter-effects both in the cost and quality of care, especially as observed through the lenses of social determinants of health (SDoH) and COVID. The Society of Actuaries seeks a deeper understanding of these effects and counter-effects.

LOI: July 5, 2021

Application Deadline: Oct 1, 2021

More Information

07/07/2021 - National Institutes of Health/DHHS - RFA-OD-21-009 -- Emergency Award: RADx-UP - Social, Ethical, and Behavioral Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01 Clinical Trials Optional)

High rates and disparities of COVID-19 infection, morbidity, and mortality continue among underserved and vulnerable populations across the United States. The overarching goal of the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative is to understand and ameliorate factors that have placed a disproportionate burden of the pandemic on underserved and/or vulnerable populations, specifically by implementing programs that expand the scope and reach of COVID-19 testing interventions to reduce these disparities. To address barriers to testing and vaccination, social, ethical, and behavioral research is urgently needed to inform related mitigation efforts. This Phase II RADx-UP Funding Opportunity Announcement (FOA) is designed to expand research to understand and address the social, ethical, and behavioral implications (SEBI) of COVID-19 testing interventions among underserved and vulnerable populations. Desirable studies for Phase II will move beyond descriptive health disparities research to focus on developing interventions and other actionable solutions in collaboration with community partners and stakeholders. The funding for this initiative is provided from the American Rescue Plan Act of 2021.

Application Deadline: July 07, 2021

More Information

07/07/2021 - National Institutes of Health/DHHS - RFA-OD-21-008 -- Emergency Awards: Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations – RADx-UP Phase II (U01 Clinical Trial Optional)

This funding opportunity announcement (FOA) uses an emergency U01 mechanism to support Phase II of the Rapid Acceleration of Diagnostics – Underserved Populations (RADxSM-UP) initiative. These two-year Testing Research Projects will (1) expand the scope and reach of RADxSM-UP testing interventions to reduce COVID-19 disparities among underserved and vulnerable populations and (2) address scientific questions on interventions to increase access and uptake of COVID-19 testing given the increasing availability of SARS-CoV-2 vaccines. The funding for this initiative is provided from the American Rescue Plan Act of 2021.

Application Deadline: July 07, 2021

More Information

07/16/2021 - 23andme - Research Innovation Collaborations Program

23andMe endeavors to advance biomedical science through genetic research. The 23andMe Research Innovation Collaborations Program pairs up academic researchers with 23andMe scientists to perform analyses. Through this program, academic researchers can access de-identified, aggregated data from the 23andMe Research Cohort.

Application Deadline: July 17, 2021

More Information

07/20/2021 - National Institutes of Health/DHHS - RFA-CA-21-029 -- Centers on Telehealth Research for Cancer-Related Care (P50 Clinical Trial Required)

The purpose of this Funding Opportunity Announcement (FOA) is to fund P50 Centers dedicated to advancing a national telehealth research agenda focused on improving cancer-related care and outcomes across the cancer control continuum in a rapidly changing healthcare, policy, technology, and communication environment. Centers are expected to generate and disseminate a robust evidence base for patient-centered, sustainable telehealth models of cancer care delivery. Centers will foster innovations to improve cancer care delivery by researching real-time, patient-provider telehealth communication using new tools, research methods, and technologies. Each Center will focus on one overarching cancer-focused telehealth research theme that will frame the Center’s scientific activities. Each Center will leverage a clinical practice network able to support multiple cancer-focused telehealth research studies, including two rapid-cycle pilot projects and one large-scale pragmatic randomized control trial. A centerpiece of each Center, the pragmatic trial will evaluate the integration of telehealth-delivered cancer care into a real-world clinical environment, evaluating improvements in patient access, quality of care, patient-provider communication, and health outcomes. Centers will disseminate evidence-based approaches to telehealth-focused cancer care to the broader clinical care and cancer control communities. Collectively, the P50 Centers on Telehealth Research for Cancer-Related Care will represent a national initiative at the forefront of cancer-related telehealth research committed to improving access to care, care quality, patient-provider communication, and health outcomes across the cancer control continuum.

LOI (Optional): June 20, 2021

Application Deadline: July 20, 2021

More Information

07/30/2021 - National Institutes of Health/DHHS - RFA-AI-21-023 -- Respond: Epidemiology to End the HIV Epidemic (RESPOND: EEE) (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support applications that address the RESPOND pillar of the Ending the HIV Epidemic: A Plan for America (EHE) initiative. The objective is to better understand HIV susceptibility and ongoing transmission in the United States (U.S.) using local and population-level epidemiology in collaboration with implementing partners. Data generated through this research will inform intervention approaches and facilitate more timely evaluation of context-specific HIV control strategies towards the goal of ending the HIV epidemic in the U.S.

LOI (Optional): June 30, 2021

Application Deadline: July 30, 2021

More Information

August 2021 Application Deadlines

08/17/2021 - National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS - RFA-AA-21-002 -- SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) will support research grants to address urgent, time-sensitive research questions on the relationships between alcohol consumption and COVID-19 related outcomes and consequences. The principal area of focus is research that can improve public health in the near term by informing responses to the current COVID-19 pandemic, in view of 1) the impact of alcohol misuse on incidence and severity of COVID-19 disease or 2) the effect of the COVID-19 disease and pandemic-induced restrictions on alcohol use and alcohol use disorder (AUD). Time-sensitive applications for which standard NIH review and funding timelines would compromise either the ability to conduct the research or the value of the knowledge and with the potential to inform responses to the current pandemic will be considered. Applications to this RFA should be accomplished within a three year project duration .

Application Deadline: August 17, 2021

More Information

08/17/2021 - National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS - RFA-AA-21-004 -- SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R21 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) will support research grants to address urgent, time-sensitive research questions on the relationships between alcohol consumption and COVID-19 related outcomes and consequences. The principal area of focus is research that can improve public health in the near term by informing responses to the current COVID-19 pandemic, in view of 1) the impact of alcohol misuse on incidence and severity of COVID-19 disease or 2) the effect of the COVID-19 disease and pandemic-induced restrictions on alcohol use and alcohol use disorder (AUD). Time-sensitive applications for which standard NIH review and funding timelines would compromise either the ability to conduct the research or the value of the knowledge and with the potential to inform responses to the current pandemic will be considered. This FOA uses the R21 grant mechanism, which is intended to support investigation of novel scientific ideas or new model systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research.

Application Deadline: August 17, 2021

More Information

08/17/2021 - National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS - RFA-AA-21-003 -- SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R03 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) will support research grants to address urgent, time-sensitive research questions on the relationships between alcohol consumption and COVID-19 related outcomes and consequences. The principal area of focus is research that can improve public health in the near term by informing responses to the current COVID-19 pandemic, in view of 1) the impact of alcohol misuse on incidence and severity of COVID-19 disease or 2) the effect of the COVID-19 disease and pandemic-induced restrictions on alcohol use and alcohol use disorder (AUD). Time-sensitive applications for which standard NIH review and funding timelines would compromise either the ability to conduct the research or the value of the knowledge and with the potential to inform responses to the current pandemic will be considered. This FOA uses the R03 mechanism, which is intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.

Application Deadline: August 17, 2021

More Information

08/24/2021 - National Institutes of Health/DHHS - RFA-MD-21-004 -- Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 Clinical Trial Optional)

This initiative will support (1) observational research to understand the role of structural racism and discrimination (SRD) in causing and sustaining health disparities, and (2) intervention research that addresses SRD in order to improve minority health or reduce health disparities.

LOI (Optional): July 20, 2021

Application Deadline: August 24, 2021

More Information

08/27/2021 - COVID-19 Private Sector Engagement & Partnership Fund

The U.S. Department of State, Office of Global Partnerships (E/GP) is pleased to announce the COVID-19 Private Sector Engagement & Partnership Fund (Fund) Annual Program Statement (APS) that will be used make assistance awards. Through this APS, the Department of State (DOS) announces its desire to engage private sector partners to expand and amplify the Department’s COVID-19 response. The Fund seeks to support private sector interventions and build upon private sector investments in response to the virus

Application Deadline: August 27, 2021

More Information

September 2021 Application Deadlines

09/14/2021 - RFA-DA-22-005 -- Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R21 - Clinical Trial Not Allowed)

This funding opportunity announcement (FOA) invites mechanistic studies on the impact of social inequality on the brain and on the substance use trajectory. Applications investigating relevant mechanisms at the behavioral, cognitive, neurocircuitry, cellular, genetics, and epigenetics levels are encouraged. Exploratory and high-risk research projects are appropriate for this FOA. Applications testing a fully conceptualized and hypothesis-based solid premise founded with adequate preliminary data should consider applying to the companion R01 announcement RFA-DA-22-007.

LOI Deadlines: Sept 14, 2021

Application Deadlines: Oct 14, 2021

More Information

09/14/2021 - RFA-DA-22-024 -- Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R01 Basic Experimental Studies with Humans Required)

This funding opportunity announcement (FOA) invites mechanistic studies on the impact of social inequality on the brain and on the substance use trajectory. Applications investigating relevant mechanisms at the behavioral, cognitive, neurocircuitry, cellular, genetics, and epigenetics levels are encouraged. Applications testing a fully conceptualized and hypothesis-based solid premise founded with adequate preliminary data are appropriate for this FOA. Applicants with exploratory and high-risk research projects should consider applying to the companion R01 announcement RFA-DA-22-030.

LOI Deadlines: Sept 14, 2021

Application Deadlines: Oct 14, 2021

More Information

09/14/2021 - RFA-DA-22-030 -- Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R21 - Basic Experimental Studies with Humans Required)

This funding opportunity announcement (FOA) invites mechanistic studies on the impact of social inequality on the brain and on the substance use trajectory. Applications investigating relevant mechanisms at the behavioral, cognitive, neurocircuitry, cellular, genetics, and epigenetics levels are encouraged. Exploratory and high-risk research projects are appropriate for this FOA. Applicants with projects testing a fully conceptualized and hypothesis-based solid premise founded with adequate preliminary data should consider applying to the companion R01 announcement RFA-DA-22-024.

LOI Deadlines: Sept 14, 2021

Application Deadlines: Oct 14, 2021

More Information

October 2021 Application Deadlines

10/05/2021 to 09/07/2024 - National Institutes of Health/DHHS - Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Populations with Health Disparities (R01 Clinical Trial Optional)

This initiative will support innovative research to develop, test and evaluate multi-level/multi-component strategies (including models of health care) to effectively adapt and implement comprehensive clinical care for individuals with Type 2 diabetes mellitus from populations with health disparities concordant with recommended and evidence-based guidelines.

Application Deadlines: 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024

More Information

10/31/2021 - FCO -- AMENDMENT -- Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)

Description We appreciate your interest in partnering with BARDA. Due to the COVID-19 response, any white papers or full proposals submissions, other than those that are in support of COVID-19, will be put into a queue. Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interest. BARDA will not be able to meet the timelines highlighted in the Broad Agency Announcement. Thank you for understanding this unprecedented response and delays that will occur. The latest BARDA Broad Agency Announcement (BAA) is amendment 16 posted on April 24, 2020. Note: COVID-19 response related Areas of Interest includes: AOI 7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms AOI 7.7.2 Point-of-care diagnostic assay for detection of SARS-CoV-2 virus AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection), Including Serology Tests AOI 8.3 COVID-19 Vaccine AOI 9.2 COVID-19 Therapeutics AOI 9.3 Immunomodulators or therapeutics targeting lung repair AOI 9.5 Pre-exposure and post-exposure prophylaxis AOI 10 Respiratory protective devices AOI 11 Ventilators AOI 17 Advanced Manufacturing Technologies All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA clarified the language for rolling review of COVID-19 response related full proposals. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals.

Application Deadlines: October 31, 2021

More Information

November 2021 Application Deadlines

11/08/2021 - National Institutes of Health/DHHS - Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium (U01 Clinical Trial Not Allowed)

The purpose of this FOA is to advance research on the impact of SARS-CoV-2 and associated mitigation efforts on individual, family, and community behavior and on how subsequent economic disruption affects health-related outcomes, with close attention to underserved and vulnerable populations. To address these questions, this FOA aims to form a research consortium to access, extract, integrate, share, and analyze existing data from various sources with broad population coverage including underserved and vulnerable populations. Examples of existing data include public health data; personal digital data; economic, labor, and commerce data; electronic health records (EHRs); claims data; and ongoing health, demographic, and social surveys. This FOA solicits applications for individual population research projects that will be linked to a Social, Behavioral, and Economic Research on COVID-19 Consortium Coordination Center (SBECCC) to foster collaboration and synergies across consortium member projects. Investigators will work with the SBECCC to enhance as well as share data resources used in proposed research both within the consortium as well as with others for health research purposes. The SBECCC will organize annual meetings of the consortium investigators to share results, foster harmonization among measures collected, identify new opportunities for interaction/collaboration, and share results with NIH and the public. Further, the SBECCC will support the development of reports and analyses summarizing and integrating the findings/products of the consortium.

Application Deadlines: 08-Nov-2021

More Information

December 2021 Application Deadlines

12/07/2021 to 12/10/2024 - National Institute for Occupational Safety & Health/CDC/DHHS - Cooperative Research Agreements Related to the World Trade Center Health Program (U01)

The purpose of this announcement is to help address the Zadroga Act research mandate (Public Law 111–347), and in consultation with the World Trade Center (WTC) Scientific/Technical Advisory Committee, NIOSH is soliciting applications for scientifically rigorous research (Title 42 USC §300mm–51) to help answer critical questions about: Physical and mental health conditions that may be related to the September 11, 2001, terrorist attacks; Diagnosing WTC-related health conditions for which there has been diagnostic uncertainty; and Treating WTC-related health conditions for which there has been treatment uncertainty.

Application Deadline: 07-Dec-2021 , 06-Dec-2022 , 05-Dec-2023 , 10-Dec-2024

More Information

12/31/2021 - NY Life Foundation - Brave of Heart Fund

Together, New York Life and Cigna, through their foundations, created the Brave of Heart Fund, dedicated to providing healthcare workers and their families with peace of mind. The Fund is designed to provide financial support in the form of charitable relief grants to support the families of healthcare workers who lose their lives to COVID-19. In addition, Cigna behavioral health will provide emotional support and services.

Application Deadline: Dec 31, 2021

More Information

February 2023 Application Deadlines

02/03/2023 - BARDA's Division of Research, Innovation & Ventures (DRIVe) Easy Broad Agency Announcement

Please see Special Instructions 001 Issuance for Easy Broad AgencyAnnouncement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions, BARDA is temporarily suspending AOIs 1-3 as part of itsEZ-BAA (BAA-20-100-SOL-0002), but is pleased to announce that it is now accepting abstract submissions for AOI #4: 2019-nCoV. See attachment(s).This Easy Broad Agency Announcement (EZ-BAA) sets forth areas of interest(AOIs) for the Division of Research, Innovation, and Ventures (DRIVe) inthe Office of Biomedical Advanced Research and Development Authority(BARDA), issued under paragraph 6.102(d)(2)(i) of the Federal AcquisitionRegulation (FAR). Abstract submissions selected for award are consideredto be the result of full and open competition and in full compliance with41 U.S.C.

Application Deadline February 3, 2023

More Information

GCO Funding Opportunities

Monthly and continuous submission funding opportunity packets are available on the GCO Funding Opportunities web page.

STAY CONNECTED

Sign up for the Research Listserv to stay up to date with the latest news and events.